Clinical trial
A Single-center, Randomized, Double-blind, Single and Multiple Dosing, Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
NCT04536532 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Randomized, Double-blind, Single and Multiple Dosing, Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 9, 2020
- Completion date
- March 12, 2023
- Enrollment
- 52 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.